Posted on:Weil in the News
Weil advised Blackstone in its acquisition of a majority stake in ZO Skin Health, Inc., a manufacturer of a comprehensive suite of products designed to restore skin to a healthy state, from Dr. Zein Obagi, founder of ZO, Obagi family trusts, and Rohto Pharmaceuticals Co., Ltd., a manufacturer and marketer of pharmaceutical and cosmetic products, including eyewash, bath soaps, gastrointestinal medicine and hand cream. The transaction closed on October 02, 2020. Terms of the transaction have not been disclosed.
The Weil team that advised Blackstone was led by Private Equity partner Christopher Machera and included Private Equity associates Brittany Butwin, Jenna McBain, Brian Howton and Lauren Burgos. The team also included Executive Compensation & Benefits partner Amy Rubin; Executive Compensation & Benefits associates Amanda Rosenblum and Manleen Singh (Admitted in Illinois Only); Technology & IP Transactions partner Jeffrey Osterman; Technology & IP Transactions/Privacy associates Robert Brown, Rami Sherman and Meggin Bednarczyk; Real Estate partner Beatriz Azcuy; Regulatory Transactions counsel John O’Loughlin; Antitrust partner Michael Naughton; International Arbitration & Trade associate Nathan Cunningham; Complex Commercial Litigation partner Jessica Falk; Employment Litigation associate Omar Abdel-Hamid (Not Yet Admitted in New York); and White Collar Defense, Regulatory and Investigations partner Holly Loiseau.